



RECEIVED

TECH CENTER 1600/2900

PATENT AUG 1 5 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

in re application of: Batist et al.	
Application No.: 09/739,223	Group No.:
Filed: December 18, 2000	Examiner:
For: HEX II TUMOR-SPECIFIC PROMOTER AND US	SES THEREOF

Assistant Commissioner for Patents Washington, D.C. 20231

REQUEST FOR CORRECTED FILING RECEIPT

- Attached is a copy of the official filing receipt received from the PTO in the above application for which issuance of a corrected filing receipt is respectfully requested.
- 2. There is an error with respect to the following data, which is:

[X] incorrect	ly entered
---------------	------------

and/or

[] omitted.

CERTIFICATE OF MAILING/TRANSMISSION (37 C.F.R. SECTION 1.8a)

I hereby certify that this correspondence is, on the date shown below, being:

MAILING

[X] deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: 6/11/01

FACSIMILE

[] transmitted by facsimile to the Patent and Trademark Office (703) _____.

tinna L. Mana
(type or print name of person certifying)

(Request for Corrected Filing Receipt--page 1 of 2)

Error in

Correct data

Ι.	Applicant's name	1.	
2.	[] Applicant's address	2.	
3.	[] Title	3.	
4.	[X] Filing Date		December 18, 2000 (see attached copy of postcard nd Express Mail receipt
5.	[] Serial Number	5.	
6.	[] Foreign/PCT Application Re:	6.	
7.	[] Domestic Priority	7.	

3. (complete the following applicable item)

A. The correction(s) is/are not due to any error by applicant and no fee is due.

SIGNATURE OF PRACTITIONER

Tel. No.: (617) 345-6057

Customer No.: 26770

Reg. No.: 34,235

David S. Resnick NIXON PEABODY LLP 101 Federal Street Boston, MA 02110

ctitioner's Docket No. 701826-50008 CIP

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Batist et al.

Application No.: 09/739,223

Group No.:

Filed: December 18, 2000

Examiner

For: HEX II TUMOR-SPECIFIC PROMOTER AND USES THEREOF

The Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

Certificate of Mailing

I hereby certify that the following items are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to The Commissioner of Patents and Trademark, Washington, DC 20231, on this 11th day of June, 2001:

- 1. Request for Corrected Filing Receipt (2 pp);
- 2. Copy of postcard and Express Mail receipt;
- 2. Copy of Filing Receipt;
- 3. Return Receipt Postcard.

me Way



RECEIVED

AUG 1 5 2001 TECH CENTER 1600/2900

Mailing Date: 18 December 2000 Client: | Swabey Ogilvy Renault Attorney/Sec: DSR/nmq Docket No.: 701826-050008

Inventors: Batist, et al of the serial No.: (CIP of 0.5519Ser #09/276,005) and No.: Grant Date:

Filing Date: Herewith (25 March 1999) The stating stamp of the Patent and Trademark Office hereon will be taken as the date of filing

New Application Transmittal [8 pgs];
Application: Specification 32 pages; Claims 3 pages; 15 Sheets of Drawings; Abstract3 pg [2] pp.). Combined Declaration for Utility or Design Patent Application (37 C.F.R. 1.63) and Power of Automy — Executed by Gerald Butist and Maha Katabi [3 pp.]; 2.

Express Mail Certificate - Label No. EL565095350US [1 pg]. 3.

Cheque in the Amount of \$575.00;

Return Receipt Postcard.

5.





AUG 1 5 2001 TECH CENTER 1600/2900





RECEIVED Page 1 of 4



United States Patent and Trademark Office

TECH CENTER 1600/290

UNITED STATES PATENT AND TRADEMARK OFFICE

H. D.C. 2023 www.uspto.gov GRP ART UNIT | FIL FEE REC'D | ATTY DOCKET NO | DRAWINGS | TOT CLAIMS IND CLAIMS APPLICATION NUMBER FILING DATE

09/739 223

-12/19/2000 12/18/2000

1645

701826-05008-CIP

15

25

Nixon Peabody LLP c/o David S. Resnick 101 Federal Street Boston, MA 02110-1000

MAR 1 9 7001 VIXON PEAP

CONFIRMATION NO. 3120 FILING RECEIPT

OC00000005851448

Date Mailed: 03/12/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER. FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the request d corrections (if appropriate).

Applicant(s)

Gerald Batist, Montreal, CANADA; Maha Katabi, Montreal, CANADA;

Continuing Data as Claimed by Applicant

THIS APPLICATION IS A CIP OF 09/276,005 03/25/1999 WHICH IS A CON OF PCT/CA97/00691 09/22/1997 AND CLAIMS BENEFIT OF 60/026,678 09/25/1996

Foreign Applications

If Required, Foreign Filing License Granted 03/08/2001

Projected Publication Date: 06/21/2001

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

Hex II tumor-specific promoter and uses thereof

Preliminary Class

536

Data entry by : ROBINSON, FELICIA

Team : OIPE

Date: 03/12/2001

LICENSE FOR FOREIGN FILING UNDER Title 35, United States C de, Section 184 Title 37. Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CRF 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to sepionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, or other agencies, particularly the Office of Defense Trade Controts, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreian Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application.
 They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- · The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, DC 20231